Patents Assigned to Baylor College of Medicine
  • Publication number: 20190374589
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 12, 2019
    Applicant: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Patent number: 10500265
    Abstract: Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: December 10, 2019
    Assignee: Baylor College of Medicine
    Inventors: Carlos A. Ramos, Cliona M. Rooney, Sandhya Sharma, Benjamin Hyun Joon Shin, Alex Salyer
  • Patent number: 10485486
    Abstract: A system generates and displays a clinical metric based on continuously collected patient physiological data, wherein the clinical metric provides a predictive measure of the likelihood of the onset of a cardiorespiratory deterioration event in the patient in a predetermined time period in the future. If the clinical metric has a configured relationship with a predetermined threshold value, embodiments may generate an alarm in addition to or instead of displaying the clinical metric. The clinical metric thus allows clinical staff to take medically indicated actions to prevent or reduce the effects of the predicted deterioration.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: November 26, 2019
    Assignee: Baylor College of Medicine
    Inventors: Craig Rusin, Kenneth M. Brady, Eric Vu, Sebastian Acosta, Daniel J. Penny
  • Patent number: 10470446
    Abstract: Embodiments of the disclosure concern compositions and methods for genetic engineering related to hypermethylation of sequences. In particular embodiments, there are methods and compositions to induce DNA methylation in a manner that leads to transcriptional suppression of a target gene that allows characterization of the gene and/or its expression.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 12, 2019
    Assignee: Baylor College of Medicine
    Inventor: Lanlan Shen
  • Patent number: 10426418
    Abstract: One aspect of the invention provides a phantom including a confined fluidic path defining a plurality of regions of monotonically decreasing, discrete cross-sectional dimensions with respect to an imaging plane. Another aspect of the invention provides a method of assessing imaging. The method includes: placing a phantom as described herein within an imaging system; flowing one or more fluids through the phantom; and capturing one or more images of the phantom. Another aspect of the invention provides a kit for assessing imaging. The kit includes a phantom as described herein and instructions for use.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: October 1, 2019
    Assignee: Baylor College of Medicine
    Inventors: Goetz Benndorf, James Ryan Mason
  • Patent number: 10420824
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: September 24, 2019
    Assignee: Baylor College of Medicine
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • Patent number: 10420685
    Abstract: One aspect of the invention provides a mobile clinic including: an intermodal container defining at least a first opening and a second opening; a partition wall located within the intermodal container, the partition wall separating the intermodal container into an anteroom and a treatment room; and an access control device programmed to prevent passage from the anteroom into the treatment room until a user's donning of personal protective equipment is verified. Another aspect of the invention provides a collapsible structure including: a rigid base; a rigid roof; one or more collapsible walls extending between the floor and the base; and an erector system comprising four cross-bars. Another aspect of the invention provides a crate including: a bottom panel; a top panel; and a plurality of walls, wherein at least two of said plurality of wails including one or more conduits.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: September 24, 2019
    Assignee: Baylor College of Medicine
    Inventors: Sharmila Anandasabapathy, Sarah Michel, Caroline Popper
  • Patent number: 10385316
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 20, 2019
    Assignees: Baylor College of Medicine, Wilson Wolf Manufacturing
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Patent number: 10385080
    Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 20, 2019
    Assignees: Board of Regents, The University of Texas System, Baylor College of Medicine
    Inventors: John S. McMurray, Pijus Kumar Mandal, Pietro Morlacchi, Morgan Knight, David B. Corry
  • Patent number: 10377819
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 13, 2019
    Assignees: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20190224476
    Abstract: Wireless treatment of arrhythmias. At least some of the example embodiments are methods including: charging a capacitor of a first microchip device abutting heart tissue, the charging by harvesting ambient energy; charging a capacitor of a second microchip device abutting the heart tissue, the charging of the capacitor of the second microchip device by harvesting ambient energy; sending a command wirelessly from a communication device outside the rib cage to the microchip devices; applying electrical energy to the heart tissue by the first microchip device responsive to the command, the electrical energy applied from the capacitor of the first microchip device; and applying electrical energy to the heart tissue by the second microchip device responsive to the command to the second microchip device, the electrical energy applied from the capacitor of the second microchip device.
    Type: Application
    Filed: August 22, 2017
    Publication date: July 25, 2019
    Applicants: WILLIAM MARSH RICE UNIVERSITY, TEXAS HEART INSTITUTE, BAYLOR COLLEGE OF MEDICINE
    Inventors: Yuxiang SUN, Aydin BABAKHANI, Mehdi RAZAVI, David BURKLAND, Brian GREET, Mathews JOHN, Hongming LYU
  • Publication number: 20190216810
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Application
    Filed: March 22, 2019
    Publication date: July 18, 2019
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Patent number: 10351824
    Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: July 16, 2019
    Assignees: Cell Medica Limited, Baylor College of Medicine
    Inventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
  • Patent number: 10328127
    Abstract: Embodiments of the disclosure concern methods and compositions that relate to increasing or decreasing the weight (including, for example, by increasing or decreasing the adipose mass) in individuals in need thereof. Such methods and compositions, in particular embodiments, concern providing an effective amount of the hormone asprosin to increase adipose mass in an individual with insufficient adipose mass and providing an antibody or inhibitor of asprosin in an individual with obesity or diabetes, for example, to reduce adipose mass.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 25, 2019
    Assignee: Baylor College of Medicine
    Inventors: Atul Chopra, David D. Moore
  • Publication number: 20190175397
    Abstract: The present disclosure concerns hyperthermic devices for treating vascular involvements related to cancer therapies, such as surgery. In specific embodiments, the device is configured to provide therapeutic heating to destroy vessel-encasing tumors while still protecting the vessel itself. In particular embodiments, the devices utilize two opposing semi-cylindrical shells that encase the vessel in need of treatment of a tumor thereon. In other devices, a flexible substrate is guided under and around the vessel and tumor thereon.
    Type: Application
    Filed: May 12, 2017
    Publication date: June 13, 2019
    Applicant: Baylor College of Medicine
    Inventors: Stuart James Corr, Matthew James Ware, Steven A. Curley, Lam Nguyen
  • Patent number: 10301647
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: May 28, 2019
    Assignee: Baylor College of Medicine
    Inventors: Brendan Lee, Kilian Guse, Zhechao Ruan
  • Patent number: 10301671
    Abstract: Embodiments of the disclosure encompass methods of amplifying nucleic acid from one or more cells using MALBAC (multiple annealing and looping-based amplification cycles) primers. In particular embodiments, the nucleic acid is amplified as amplicons in a linear manner. Specific embodiments include the removal or effective destruction of nonlinearly produced amplicons.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 28, 2019
    Assignee: Baylor College of Medicine
    Inventors: Chenghang Zong, Michael Gundry, Kuanwei Sheng
  • Patent number: 10286065
    Abstract: Embodiments are directed to compositions and methods for treating viral infections.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 14, 2019
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE, PULMOTECT, INC.
    Inventors: Burton Dickey, Scott Evans, Brian Gilbert, Diane Markesich, Brenton Scott, Michael Tuvim
  • Patent number: 10280470
    Abstract: Embodiments of the invention include methods and/or compositions for analysis of samples for C. difficile infection to determine whether or not an individual is at risk for having recurrent C. difficile infection or a CDI misdiagnosis. Methods include characterization of microflora composition from the gut, wherein alterations of the microflora gut composition are indicative of recurrence of infection. Methods include analysis of nucleic acids from the gut, such as 16S rRNA as being identifying of a particular bacteria in the analysis of bacterial populations of the gut.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Tor Savidge, Emily Hollister-Branton
  • Patent number: 10279009
    Abstract: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Juan Fernando Vera Valdes, Malcolm Brenner, Usanarat Anurathapan